Chloasma Clinical Trial
Official title:
Identification of Biological Markers and Biometrological Characterization of Melasma
Melasma (also called chloasma and pregnancy mask) is characterized by pigmented lesions
darker than their usual complexion on the faces of affected subjects.
The physiopathology of melasma is still poorly understood. To date, the factors that favor
the onset of melasma appear to be: genetic predisposing factors, changes in sex hormone
levels, and sun exposure.
Vascularization as well as elastosis also appear to be increased in skin with melasma.
The aim of this study is to evaluate the different levels of expression of biomarkers between
pigmented melasma lesions and surrounding healthy skin when melasma is highly pigmented but
also when it is dormant (ie treated melasma, without UV solicitation in the heart of winter).
The goal is to identify and better understand the involvement of different genes and proteins
and thus offer more specific ways of care, and therefore effective, for the subjects.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT03585179 -
Oral and Topical Tranexamic Acid for the Treatment of Melasma
|
Phase 3 | |
| Recruiting |
NCT06418568 -
Efficacy and Safety Trial of Using Ultra-Pulsed Shockwaves to Deliver Tranexamic Acid for the Treatment of Melasma
|
N/A |